144 related articles for article (PubMed ID: 9150900)
1. Serum concentration of tumor necrosis factor in patients with breast cancer.
Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
Breast Cancer Res Treat; 1997 May; 43(3):211-5. PubMed ID: 9150900
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of transforming growth factor beta1 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Sheen CW; Eng HL; Chen WJ
Arch Surg; 2001 Aug; 136(8):937-40. PubMed ID: 11485532
[TBL] [Abstract][Full Text] [Related]
4. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of matrix metalloproteinase 2 in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Sheen CC; Chen WJ
Cancer Lett; 2001 Nov; 173(1):79-82. PubMed ID: 11578812
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer.
Sheen-Chen SM; Eng HL; Sheen CW; Cheng YF; Chou FF; Chen WJ
Anticancer Res; 1997; 17(4A):2823-6. PubMed ID: 9252723
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of tumor necrosis factor alpha correlate with response to neoadjuvant chemotherapy in locally advanced breast cancer.
Berberoglu U; Yildirim E; Celen O
Int J Biol Markers; 2004; 19(2):130-4. PubMed ID: 15255545
[TBL] [Abstract][Full Text] [Related]
8. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.
Ma Y; Ren Y; Dai ZJ; Wu CJ; Ji YH; Xu J
Adv Clin Exp Med; 2017; 26(3):421-426. PubMed ID: 28791816
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
10. The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy.
Wen J; Ye F; Huang X; Li S; Yang L; Xiao X; Xie X
Tumour Biol; 2016 Jun; 37(6):7493-500. PubMed ID: 26678892
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer.
Sheen-Chen SM; Chen WJ; Eng HL; Sheen CC; Chou FF; Cheng YF
Cancer Invest; 1999; 17(8):581-5. PubMed ID: 10592765
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy.
Hofmann G; Balic M; Dandachi N; Resel M; Schippinger W; Regitnig P; Samonigg H; Bauernhofer T
Clin Biochem; 2013 Oct; 46(15):1585-9. PubMed ID: 23792261
[TBL] [Abstract][Full Text] [Related]
13. Serum-soluble interleukin-2 receptor concentrations in patients with breast cancer: a preliminary report.
Sheen-Chen SM; Chen WJ; Eng HL; Chou FF
Changgeng Yi Xue Za Zhi; 1998 Jun; 21(2):133-8. PubMed ID: 9729645
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
15. Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer.
Papadopoulou E; Tripsianis G; Anagnostopoulos K; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Int J Biol Markers; 2010; 25(3):126-35. PubMed ID: 20872355
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic analysis of the nipple-areolar complex occult involvement in early stage breast carcinoma].
Wang SY; Peng DF; Cai ZG; Zhang RZ; Yao TJ; Zhang H; Yang M; Dong HM
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):203-6. PubMed ID: 18756937
[TBL] [Abstract][Full Text] [Related]
17. Serum level of angiogenin in breast cancer.
Sheen-Chen SM; Eng HL; Chen WJ; Chou FF; Chen HS
Anticancer Res; 2000; 20(6C):4769-71. PubMed ID: 11205216
[TBL] [Abstract][Full Text] [Related]
18. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor: A novel tumor marker for breast cancer.
Pai P; Kittur SK
J Cancer Res Ther; 2023 Apr; 19(Supplement):S0. PubMed ID: 37147943
[TBL] [Abstract][Full Text] [Related]
20. [Evidence-based radiotherapy in the treatment of early-stage invasive breast cancer: traditional clinical features and biomarkers].
Fodor J
Magy Onkol; 2009 Mar; 53(1):7-14. PubMed ID: 19318321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
